Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN65,1165,142,13
Msft-0,17
Nokia3,29053,2965-1,02
IBM0,08
Mercedes-Benz Group AG73,8573,870,39
PFE-0,11
29.03.2024 1:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 28.03.2024 17:00:00
Orion (ORNBV.HE, Helsinki)
Závěr k 28.3.2024 Změna (%) Změna (EUR) Objem obchodů (EUR)
34,57 0,26 0,09 8 144 928
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 29.03.2024
Popis společnosti
Obecné informace
Název společnostiOrion Oyj
TickerORNBV
TickerORNAV
Kmenové akcie:Ordinary Shares Class B
Kmenové akcie:Ordinary Shares Class A
RICORNAV.HE
RICORNBV.HE
ISINFI0009014377
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky31.12.2023
Počet zaměstnanců k 31.12.2023 3 632
Akcie v oběhu k 08.02.2024 140 351 305
MěnaEUR
Kontaktní informace
UliceOrionintie 1A
MěstoESPOO
PSČ02200
ZeměFinland
Kontatní osobaJari Karlson
Funkce kontaktní osobyChief Financial Officer, Member of the Executive Management Board
Telefon 358 104 261
Fax358104264435
Kontatní telefon358 104 262 883

Business Summary: Orion Oyj, previously Orion Corporation, is a Finland-based company active within the pharmaceutical industry. The Company is engaged in the research and development, manufacture and marketing of human and veterinary pharmaceuticals and active pharmaceutical ingredients. The core therapy areas of the Company's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Orion Oyj revenues decreased 11% to EUR1.19B. Net income decreased 38% to EUR216.8M. Revenues reflect North America segment decrease of 48% to EUR174.5M, Other Europe segment decrease of 8% to EUR366.5M. Net income also reflects Other Sales and marketing expenses increase of 7% to EUR217.3M (expense), Other Administrative Expenses increase of 8% to EUR67M (expense).
Odvětvová klasifikace
TRBC2012Pharmaceuticals (NEC)
RBSS2004Pharmaceuticals - Generic & Specialty
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSMedicinal and Botanical Manufacturing
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Medicinal & Botanical Mfg
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Medicinal and Botanical Manufacturing
SICPharmaceutical Preparations
SICMedicinals And Botanicals



  • Poslední aktualizace: 29.03.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, Member of the Executive Management BoardLiisa Hurme5701.11.202201.01.2008
Chief Financial Officer, Member of the Executive Management BoardJari Karlson6301.08.2002
Chief Financial Officer, Member of the Executive Management BoardRene Lindell4801.05.202401.05.2024
Senior Vice President - People and Culture, Member of the Executive Management BoardJulia Macharey4701.02.202401.02.2024
Senior Vice President, Generics and Consumer Health, Member of the Executive Management BoardSatu Ahomaki5801.01.202301.01.2008
Senior Vice President, Global Operations, Fermion, Member of the Executive Management BoardJuhani Kankaanpaa4401.11.202201.11.2022
Senior Vice President, Corporate Strategy and Program Management, Member of the Executive Management BoardVirve Laitinen5201.01.202301.01.2012
Senior Vice President, Animal Health, Member of the Executive Management BoardNiclas Lindstedt5801.01.202301.01.2023
Senior Vice President, Branded Products, Member of the Executive Management BoardHao Pan5301.01.202301.01.2023
Senior Vice President for Research and Development and Innovative Medicines, Member of the Executive Management BoardOuti Vaarala6201.01.202301.06.2020